Quiz 2

expert

Question 1 / 10

'This supplemental new drug application provides for the use TAXOTERE in combination with cisplatin for the treatment of ... . . What should we select as generic or innovator type for this case?

New Combination

New Formulation

New Indication

NME

medium

Question 2 / 10

What should we select as generic or innovator type for Photrex according to info given?

NME

New Combination

New Formulation

New Strength

hard

Question 3 / 10

What should we select as generic or innovator type for APD515 and APD515 Topical, respectively?

New Formulation, NME

NME, New Formulation

Nme, nme

New Combination, NME

medium

Question 4 / 10

Assume that there is a news telling us that Photrex is approved. What should we select as generic or innovator type for Photrex?

NME

New Strength

New Formulation

New Indication

expert

Question 5 / 10

Assume that there is a news telling us that Photrex is approved. What should we select as generic or innovator type for MV2101?

NME

New Formulation

New Combination

New Indication

medium

Question 6 / 10

What should we select as generic or innovator type for above product? (Hint. CYC202 is a non-approved product)

New Formulation

New Indication

New Combination

NME

medium

Question 7 / 10

How many of the rows given are incorrect?

medium

Question 8 / 10

Molecule X was only approved in Japan previously and the company is developing a new product, ABC-103, using that molecule in the USA. What should we select as type for ABC-103 in this case?

New Formulation

New Combination

NME

New Indication

hard

Question 9 / 10

'Compound X is an intraocular, polymer implant containing human retinal epithelial cells genetically modified to continually deliver... ' What should we select as type for Compound X?

New Formulation

Generic

NME

New Combination

medium

Question 10 / 10

Compound X is a subcutaneous formulation which is on market. You have a news telling that intramuscular formulation of the product is approved later on. In this case, ... ...

I create a child and select new route as type

I don't create a child and add new indication as type to first approved child

I create a child and select new indication as type

I don't create a child and add new route as type to first approved child

A mistake in this Quiz ? Contact the author

1^st	Cdemiroglu	100% (299s)
2^nd	Ayca	90% (399s)
3^rd	Oakyar	80% (298s)
4^th	Turkan	80% (376s)
5^th	Ozlemc	80% (404s)
6^th	Gonulpharmacircle	80% (461s)
7^th	Aysen	80% (475s)
8^th	Pembegul	80% (606s)
9^th	Acoban	70% (582s)
10^th	Dkonuk	60% (548s)

'This supplemental new drug application provides for the use TAXOTERE in combination with cisplatin for the treatment of ... . . What should we select as generic or innovator type for this case?

What should we select as generic or innovator type for Photrex according to info given?

What should we select as generic or innovator type for APD515 and APD515 Topical, respectively?

Assume that there is a news telling us that Photrex is approved. What should we select as generic or innovator type for Photrex?

Assume that there is a news telling us that Photrex is approved. What should we select as generic or innovator type for MV2101?

What should we select as generic or innovator type for above product? (Hint. CYC202 is a non-approved product)

How many of the rows given are incorrect?

Molecule X was only approved in Japan previously and the company is developing a new product, ABC-103, using that molecule in the USA. What should we select as type for ABC-103 in this case?

'Compound X is an intraocular, polymer implant containing human retinal epithelial cells genetically modified to continually deliver... ' What should we select as type for Compound X?

Compound X is a subcutaneous formulation which is on market. You have a news telling that intramuscular formulation of the product is approved later on. In this case, ... ...

Latest quizzes & tests

Mobile & social networks

Professionals

About us